Gilder Gagnon Howe & CO LLC Viracta Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.38 - $2.29 $1,368 - $2,271	-992 Reduced 0.61%	160,515 $255,000
Q4 2022 Feb 14, 2023	SELL	$1.26 - $4.38 $126 - $438	-100 Reduced 0.06%	161,507 $235,000
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $3,120 - $5,348	-940 Reduced 0.58%	161,607 $690,000
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $37,117 - $99,245	-19,849 Reduced 10.88%	162,547 $631,000
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $71,739 - $153,129	-32,170 Reduced 14.99%	182,396 $868,000

Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $213,037 - $500,038	63,216 Added 41.77%	214,566 $783,000
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $3,731 - $5,964	476 Added 0.32%	151,350 $1.21 Million
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $1.14 Million - $1.95 Million	150,874 New	150,874 $1.71 Million

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.